Ardent Health Partners, LLC (ARDT) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2026
Loading P/E history...
ARDT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Ardent Health Partners, LLC (ARDT) trades at a price-to-earnings ratio of 10.3x, with a stock price of $9.88 and trailing twelve-month earnings per share of $0.95.
The current P/E is 13% below its 5-year average of 11.9x. Over the past five years, ARDT's P/E has ranged from a low of 7.3x to a high of 29.4x, placing the current valuation at the 71th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ARDT trades at a 54% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ARDT trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARDT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ARDT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $96B | 15.1 | 0.72 | +29% | |
| $17B | 12.5 | 0.38Best | -53% | |
| $408M | 0.8Lowest | - | +197%Best | |
| $11B | 7.4 | 0.46 | +37% | |
| $10B | 29.8 | 2.16 | +14% | |
| $2B | 13.9 | - | -29% | |
| $897M | 41.5 | - | -23% | |
| $92B | 29.2 | 0.75 | +15% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ARDT Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $8.56 | $0.95 | 9.0x | -24% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $8.83 | $0.96 | 9.2x | -23% |
| FY2025 Q3 | $13.25 | $1.50 | 8.8x | -26% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $13.66 | $1.86 | 7.3x | -38% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $13.75 | $1.64 | 8.4x | -30% |
| FY2024 Q4 | $17.08 | $1.54 | 11.1x | -7% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $18.38 | $0.63 | 29.4x | +147% |
Average P/E for displayed period: 11.9x
See ARDT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARDT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARDT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARDT — Frequently Asked Questions
Quick answers to the most common questions about buying ARDT stock.
Is ARDT stock overvalued or undervalued?
ARDT trades at 10.3x P/E, near its 5-year average of 11.9x. The 71th percentile ranking places valuation within normal historical bounds.
How does ARDT's valuation compare to peers?
Ardent Health Partners, LLC P/E of 10.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ARDT's PEG ratio?
ARDT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2026.